Did the FDA suddenly get stringent about new drugs? Is longevity research over-hyped? And what can recovered patients teach us about Covid-19 vaccines?
We discuss all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we break down a pair of shocking FDA rejections for Gilead Sciences and BioMarin Pharmaceutical and what they might portend. Next, STAT’s Matthew Herper joins us to explain some disappointing results for Unity Biotechnology and the implications for longevity research. Finally, medicinal chemist and blogger Derek Lowe calls in to discuss the latest research on coronavirus immunity and the development of vaccines for Covid-19.
For more on what we cover, here’s the news on BioMarin’s rejection and the FDA decision on Gilead’s drug; here’s the latest on longevity research; here’s Lowe’s blog; and here’s STAT’s complete coverage of the coronavirus pandemic.
And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email email@example.com.
Interested in sponsoring a future episode of “The Readout LOUD”? Email us at firstname.lastname@example.org.